key: cord-1024112-0ek4sy5s
authors: Nishino, Mizuki; Hatabu, Hiroto; Ricciuti, Biagio; Vaz, Victor; Michael, Kesi; Awad, Mark M.
title: Brief Report Axillary lymphadenopathy after COVID-19 vaccinations in patients with thoracic malignancy: Incidence, predisposing factors, and imaging characteristics
date: 2021-09-08
journal: J Thorac Oncol
DOI: 10.1016/j.jtho.2021.08.761
sha: 4bdcedc56dbcdf6dfd3a495ae66f1ceac72665bc
doc_id: 1024112
cord_uid: 0ek4sy5s

Objective Axillary lymphadenopathy from COVID-19 vaccine is an emerging phenomenon during unprecedented mass vaccinations, which can be incidentally found on CT scans. The present study investigated the incidence, predisposing factors, and imaging characteristics of vaccine-related axillary lymphadenopathy in patients with thoracic malignancy who underwent CT scans before and after COVID-19 vaccinations. Methods The study included patients with thoracic malignancies who received two doses of mRNA-based COVID-19 vaccinations and had pre-vaccine and post-vaccine chest CT scans. Post-vaccine chest CT scans were reviewed for increase in size of axillary/subpectoral lymph nodes, comparing to the pre-vaccine scans. The cases with axillary/subpectoral lymphadenopathy were further reviewed independently by two radiologists referring to clinical information, to determine if lymphadenopathy was attributed to vaccinations. Results Vaccine-related axillary/subpectoral lymphadenopathy was noted in 21 of 232 patients (9.0%). The median short axis diameter of the largest node was 7 mm (range: 5-14 mm). The median number of increased nodes was 4 (range: 1-10). The median time to the post-vaccine scan demonstrating lymphadenopathy was 1.7 weeks (range: -2.9 – 6.6) from the 2nd dose. Vaccine-related lymphadenopathy was noted more commonly in woman than in men (18/144, 12.5% vs. 3/88, 3.4%, respectively; p=0.019), and with mRNA-1273 vaccines than BNT162b2 vaccines (6/28, 21% vs. 15/204, 7.4%, respectively; p=0.026). Conclusions The incidence of lymphadenopathy was 9%, with a median onset time of 1.7 weeks after the 2nd vaccine dose. Female sex and vaccine type (mRNA-1273 vaccine) were associated with higher frequency of lymphadenopathy, providing initial observations to inform further investigations in larger cohorts.

The coronavirus disease 2019 pandemic has affected tens of millions of people worldwide, prompting urgent needs for effective vaccinations. The mRNA-based vaccines have been given widely since the end of 2020, leading to emerging vaccine-related observations, including axillary lymphadenopathy noted on imaging. 1 Patients with cancer under active treatment or surveillance undergo frequent cross-sectional imaging, leading to the incidental detection of vaccine-related lymphadenopathy. 1, 2 Although sporadic reports exist for axillary lymphadenopathy on imaging after COVID-19 vaccinations, the details of this phenomenon remain to be investigated for its incidence, predisposing factors, and imaging characteristics. 1-3 A recent report described the findings in patients who underwent FDG-PET/CT for various malignancies. 4 CT scan is by far the most commonly used imaging modality for cancer monitoring, and patients with thoracic malignancy provide a unique opportunity to investigate this phenomenon on CT, because they undergo frequent chest CT scans that provides detailed evaluations of the axilla.

The purpose of the present report is to determine the incidence of vaccine-related axillary lymphadenopathy on post-vaccine CT scans in patients with thoracic malignancy, identify predisposing factors, and describe imaging characteristics.

The study included patients with thoracic malignancies who received two doses of COVID-19 vaccinations (Pfizer-BioNtech BNT162b2 or Moderna mRNA-1273) between December 2020 and April 2021. All patients had at least one pre-vaccine chest CT within 6 months prior the 1 st vaccine dose and underwent at least one chest CT and/or FDG-PET/CT after J o u r n a l P r e -p r o o f vaccination. Patients with existing axillary lymph node enlargement (≥10 mm in short axis) on pre-vaccine CT were excluded. The medical records and imaging studies were retrospectively reviewed in these patients who had consented to a correlative research study approved by the institutional review board at the Dana-Farber Cancer Institute.

Post-vaccine chest CT scans were reviewed by a board-certified thoracic radiologist (MN), for increase in size of lymph nodes in the axilla and subpectoral areas, based on side-byside comparison with the pre-vaccine scans. The increase of axillary lymph nodes was visually assessed, and when noted, the short axis of the largest node was measured. The number of increased nodes was counted. The radiologist was aware of the vaccination dates, however, was not aware of the type or the side (right or left) of vaccinations at the time of the initial review.

After the initial review, the cases that were positive for axillary/subpectoral lymphadenopathy on the post-vaccine scans were reviewed independently by two radiologists (MN, the first reader; and HH, another board-certified thoracic radiologist), referring to the side of vaccinations and the detailed clinical history including the disease status and treatment information, to determine if lymphadenopathy was attributed to COVID-19 vaccinations.

Demographics and disease characteristics were compared between patients with and without vaccine-related lymphadenopathy, using a Fisher exact test and Chi-squared test for categorical variables, and a Wilcoxon Rank Sum test for continuous variables.

Among a total of 232 vaccinated patients with pre-and post-vaccine CT scans without pre-existing axillary adenopathy, the initial imaging review identified 28 patients with new unilateral axillary/subpectoral lymphadenopathy on the post-vaccine scans. Lymphadenopathy J o u r n a l P r e -p r o o f was not considered to be attributed to vaccinations in 7 patients in the 2 nd review, due to contralateral vaccine injections (n=6), and because of a recent ipsilateral breast surgery with breast inflammation on the post-vaccine PET/CT (n=1). After excluding these 7 patients, vaccine-related axillary/subpectoral lymphadenopathy was noted in 21 of 232 patients (9.0%) ( Table 1 ). The median short axis diameter of the largest node was 7 mm (range: 5-14 mm)( Fig.   1 ). Only two of the 21 patients (9.5%) had nodes ≥10 mm in short axis ( Fig 1A) . The median number of increased nodes was 4 (range: 1-10). More than one node was noted in 17 patients (81%), and ≥5 nodes were noted in 6 patients (28%). Both axilla and subpectoral nodes were patients was 4.9 weeks (range: 1.0 -9.6) from the 1 st dose, and 1.7 weeks (range: -2.9 -6.6) from the 2 nd dose. Only one lymphadenopathy-positive patient had more than one post-vaccine scans, and lymphadenopathy persisted on the 2 nd scan four weeks after the first scan (6.3 weeks after the 1 st dose and 2.3 weeks after the 2 nd dose).

Vaccine-related axillary/subpectoral lymphadenopathy was significantly more common in woman than men (18/144, 12.5% vs. 3/88, 3.4%, respectively; p=0.019), and in those who J o u r n a l P r e -p r o o f received the mRNA-1273 vaccine than those who received the BNT162b2 vaccine (6/28, 21% vs. 15/204, 7.4%, respectively; p=0.026) . No significant differences were noted between patients with and without lymphadenopathy for other factors, including age, race, smoking, tumor types and stages (Table 1) . Post-vaccine scan timing, the number of timepoints, scan types, and intervals between scans and vaccines did not significantly differ between two groups (Table 1) .

Undergoing post-vaccine PET/CT scan had no significant impact on the incidence of lymphadenopathy (p=0.43).

Vaccine-related lymphadenopathy was noted in 9% of patients with thoracic malignancy on post-vaccine CT scans. Female sex and vaccine type (mRNA-1273) were associated with higher rates of lymphadenopathy. The study provides the first report on the incidence, predisposing factors, and imaging characteristics of vaccine-related lymphadenopathy on CT using the currently available cohort during the mass vaccinations for COVID-19, which can provide a basis for further studies.

Clinically, "axillary swelling or tenderness" was noted as a local reaction in 16.0% in patients aged 18-64 years and in 8.4% of patients over 65 years in a trial of mRNA-1273 vaccine. 5 The rate of lymphadenopathy identified on CT (9.0%) in the present study is comparable to the rate of clinically noted axillary swelling/tenderness in the trial. In a recent study of 169 patients who underwent FDG-PET/CT after BNT162b2 vaccinations, 29% of the patients had FDG uptake in axillary nodes, 6 which is higher than 9% based on CT size increase. This is expected because PET/CT can detect FDG-avid nodes without size increase. The J o u r n a l P r e -p r o o f incidence of lymphadenopathy among those who underwent PET/CT in our cohort is lower (3/21;14 .2%), which can be due to a small number of patients evaluated by PET/CT. The median short axis diameter of the largest node was 7 mm, ranging from 5-14 mm.

The knowledge on the size of affected nodes is important to establish imaging criteria for this new phenomenon. 1 No size criteria were available to define vaccine-related adenopathy, and thus the present study was specifically designed to carefully compare pre-and post-vaccine CT scans to identify visually notable increase of axillary/subpectoral nodes, rather than applying criteria developed for other purposes such as RECIST. 7 The present cohort with thoracic malignancies at an academic cancer center with frequent serial chest CT scans provided unique advantages, with pre-CT scans with a median of 5.4 weeks before the 1 st dose. The focus on thoracic malignancy was also advantageous as unilateral axillary lymphadenopathy is not a frequent manifestation of metastatic disease in this population, compared to other diseases such as breast cancer, melanoma, and lymphoma. 6 Most patients (19/21, 90%) who developed new lymphadenopathy had nodes <10 mm in short axis which would be considered non-pathological by RECIST 7 , consistent with the recent PET/CT report that described "normal size" of most FDG-avid nodes after vaccinations with a mean short axis of 5 mm (range: 1-16 mm). 6 However, in a minority of patients, the nodes can be bigger, measuring up to 14 mm in short axis in one patient of our study, who reportedly had decrease of the nodes on follow-up PET/CT. The maximal short axis in the PET/CT study was 16 mm, which is similar to the upper range of our observation. 6 As the differentiation of reactive and metastatic nodes are crucial for cancer patients, further studies with a larger cohort with longer follow-up is needed to identify robust size criteria for vaccinerelated lymphadenopathy.

The number of nodes in vaccine-related lymphadenopathy has not been previously reported, and ranged from 1 to 10, with the median of 4 nodes in the present study. In the setting of lymphadenopathy, an increase in number of nodes can be noted along with size increase, and thus the attention to the number of nodes is important for documenting this phenomenon. Axilla was involved in all patients, and subpectoral region was also involved in a half of the cases. It remains to be investigated if the size, number, and the extent of lymphadenopathy are related to the degree of immune response to vaccines.

Three patients demonstrated vaccine-related lymphadenopathy on CT scans performed after the 1 st dose before receiving the 2 nd dose, as early as 1 week after the 1st dose. Though the timing of lymphadenopathy detection largely depends on the timing of scans, it appears that lymphadenopathy occurs shortly after vaccination, and even with one dose. The maximum time from the 2 nd dose to the positive CT scan was 6.6 weeks, with two patients having positive CT after 6 weeks since the 2 nd dose. The recent article recommended postponing imaging at least 6 weeks after final vaccination dose 1 , which is intuitively reasonable but is not evidence-based due to a lack of data. The recent study reported persistence of FDG-avid nodes beyond 6 weeks in one-third of the vaccinated patients assessed by PET/CT. 6 These accumulating data are indicative of longer duration of vaccine-related lymphadenopathy beyond 6 weeks. Considering the needs of frequent serial scanning in cancer patients especially for those on active treatment, it is likely more realistic to precisely define the imaging characteristics of vaccine-related lymphadenopathy and establish criteria for accurate diagnosis of the phenomenon, rather than delaying imaging studies that are necessary for treatment decisions. A follow-up study is planned once a larger number of patients with longer post-vaccine follow-up becomes available.

The present study identified factors associated with vaccine-related lymphadenopathy, including female sex and mRNA-1273 vaccine. The difference of the incidence rates between women and men were quite notable (12.5% vs. 3.4%; p=0.019), which may aid diagnosis when imaging findings are equivocal. Given a small number of patients who received mRNA-1273 vaccines (n=28), the significance of the differences between two types of mRNA-based vaccine remains to be validated. The incidence of lymphadenopathy from other COVID-19 vaccines such as viral vector vaccines, along with predisposing factors and imaging characteristics needs to be addressed as well.

In conclusion, vaccine-related axillary lymphadenopathy was noted in 9% on postvaccine CT scans in patients with thoracic malignancy who received mRNA-based vaccinations.

The imaging features were characterized and candidates for predisposing factors were identified, providing the initial data for further investigations of this emerging phenomenon amid mass vaccinations against COVID-19 pandemic.

J o u r n a l P r e -p r o o f The patient underwent PET/CT at the outside institution 7 weeks after the post-vaccine CT, which reportedly showed decrease of these nodes without FDG uptake (the images not available and not shown).

Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel

Axillary Lymphadenopathy After mRNA COVID-19 Vaccination

Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients

Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by

FDG PET-CT and relevance to study interpretation

Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Mizuki Nishino: Conceptualization; Data curation; Formal analysis; Investigation; Methodology

Writing -original draft; Writing -review & editing

Hiroto Hatabu: Conceptualization; Data curation; Formal analysis; Investigation; Methodology

Biagio Ricciuti: Data curation; Investigation; Methodology; Writing -review & editing

Victor Vaz: Data curation; Investigation; Methodology; Writing -review & editing

Kesi Michael: Data curation; Investigation; Methodology; Writing -review & editing

Awad: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Supervision; Visualization; Writing -review & editing